Jay Shepard
CIK 1587788 · President and CEO · last filed 2026-07-13
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
VSAR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
MONTE SERENO, CA 95030
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Esperion Therapeutics, Inc. (ESPR) Delisted | Director | 0 | $3.18 | $0 | $0 | 10 | 2026-07-13 |
| IRWD | Director | 235,036 | $3.50 | $822.6K | $0 | 7 | 2026-06-17 |
| INO | Director | 9,209 | $0.87 | $8.0K | $0 | 12 | 2026-05-21 |
| Aravive, Inc. (ARAV) Delisted | President and CEO | 61,201 | $0.04 | $2.5K | -$99.3K | 9 | 2020-04-09 |
| Aravive, Inc. (VSAR) Delisted | President and CEO | 98,844 | — | — | -$1.36M | 13 | 2018-05-23 |
| MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted | Director | — | $0.55 | — | $0 | 4 | 2017-01-19 |
| DURECT CORP (DRRX) Delisted | Director | — | $1.91 | — | $0 | 5 | 2016-06-23 |
Recent Filings · Page 5 of 6
60 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-12-22 | Aravive, Inc. (VSAR) Delisted | Grant (A) | +223,000 | $0 | EDGAR |
| 2017-10-10 | Aravive, Inc. (VSAR) Delisted | Grant (A) | +189,000 | $0 | EDGAR |
| 2017-05-15 | Aravive, Inc. (VSAR) Delisted | Sell (S) | −9,114 | -$159.5K | EDGAR |
| 2017-02-28 | Aravive, Inc. (VSAR) Delisted | Mixed | — | -$110.9K | EDGAR |
| 2017-02-23 | Aravive, Inc. (VSAR) Delisted | Mixed | — | -$267.5K | EDGAR |
| 2017-02-06 | Aravive, Inc. (VSAR) Delisted | Sell (S) | −6,719 | -$92.0K | EDGAR |
| 2017-02-02 | Aravive, Inc. (VSAR) Delisted | Mixed | −2,807 | -$279.2K | EDGAR |
| 2017-01-31 | Aravive, Inc. (VSAR) Delisted | Mixed | +68,026 | -$206.7K | EDGAR |
| 2017-01-19 | MARINUS PHARMACEUTICALS, INC. (MRNS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-08-24 | Aravive, Inc. (VSAR) Delisted | Sell (S) | −5,442 | -$70.1K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.